Tango Therapeutics, Inc.
TNGX
Rankning i aktier
#4496
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Aktiekurs
$27.18
Senast synkroniserad: 2026-07-31
Marknadsvärde
$3.38B
Förändring (1 dag)
-1.41%
Förändring (1 år)
213.86%
Land
US
Handel Tango Therapeutics, Inc. (TNGX)
Kategori
Healthcare
Aktiekurshistorik för Tango Therapeutics, Inc. (TNGX)
Högsta slutkurs: $28.53 den 2026-07-01
Lägsta slutkurs: $10.21 den 2020-09-01
Lägsta slutkurs: $10.21 den 2020-09-01
Aktiekurshistorik för Tango Therapeutics, Inc. från 2020 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2026 (TTM) | 94.33% |
| 2025 | 186.22% |
| 2024 | -66.61% |
| 2023 | 25.09% |
| 2022 | -28.88% |
| 2021 | -3.27% |
| 2020 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
